Authored by Dr.Christina Poza-Kaderman and Saul Wisnia, this article offers some great advice for AYA’s who are challenged by a cancer diagnosis.

Survivorship follow-up care is currently a much debated topic. Questions such as, “Who is in charge of my care now that treatment is completed?” are commonly asked by survivors, and the answers are varied and often confusing. This article addresses many of those questions. It includes comments from Dr. Kevin Oeffinger, who has worked tirelessly to create quality care for survivors.

Hodgkin International’s Rachel Gingold reflects on 36 years of survivorship.

Young adulthood is full of challenges, but when a cancer diagnosis enters the picture, things get really intense, really fast. Fresh out of undergrad at 24, my life changed overnight when the symptoms I’d been having for nearly a year turned out to be Hodgkin lymphoma – cancer.

Jennifer Young, a melanoma survivor, reflects on what it meant to see her daughter reach age 19, the same age she was when she was first diagnosed. She shares how her cancer experience made her more resilient, more empathetic, and more grateful for everyday moments.

For survivors who have finished treatment and are in remission, the question “Am I cured?” is both natural and complicated. In this thoughtful patient handout, Dr. Wendy Harpham explores how the word “cure” is used in oncology, why some doctors avoid it, and what survivors truly need to focus on after treatment.

What should high-quality survivorship care look like? In this presentation, Dr. Michelle Mollica of the National Cancer Institute outlines new national standards that aim to ensure every survivor receives comprehensive, evidence-based support after treatment. From care coordination to managing long-term effects, these guidelines offer a roadmap for improving both patient outcomes and research.

Cancer survivors face a 14% higher risk of developing entirely new cancers (secondary malignancies) compared to the general population, and they account for nearly 19% of all cancer diagnoses in the U.S. Oncology Advanced Practice Providers (APPs) highlight that past treatments, especially radiation and certain chemotherapies like alkylating agents, platinum-based drugs, anthracycline topoisomerase II inhibitors, and even targeted therapies, can contribute to long-term risk.

Here is a fascinating look at cancer survival rates, innovations for treatment, and access to services around the world.

Many long-term Hodgkin lymphoma survivors face an increased risk of developing secondary cancers, often as a result of earlier treatments like chemotherapy or radiation. These risks can emerge years or even decades after treatment, making ongoing awareness and screening a critical part of survivorship care.